Format

Send to

Choose Destination
Lancet Oncol. 2015 Jan;16(1):15-7. doi: 10.1016/S1470-2045(14)71161-1. Epub 2014 Dec 29.

Expanded access programmes: patient interests versus clinical trial integrity.

Author information

1
University of Manchester/The Christie NHS Foundation Trust, Manchester, UK. Electronic address: paul.lorigan@christie.nhs.uk.
2
Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy.
3
University of Zurich, Zurich, Switzerland.
4
Gustave Roussy Cancer Campus, Villejuif Grand, Paris, France.
5
Massachusetts General Hospital, Boston, MA, USA.
6
University Medical Center Tübingen, Tübingen, Germany.
7
Department of Medicine, University of Athens, Athens, Greece.
8
University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
9
Melanoma Institute Australia, Sydney, NSW, Australia; University of Sydney, Sydney, NSW, Australia; Macquarie University, Sydney, NSW, Australia.
10
Melanoma Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.
11
Royal Marsden Hospital NHS Foundation Trust, London, UK.
12
Melanoma Institute Australia, Sydney, NSW, Australia; University of Sydney, Sydney, NSW, Australia.
13
University Hospital of Siena, Siena, Italy.
14
Peter MacCallum Cancer Centre, East Melbourne, and University of Melbourne, Parkville, VIC, Australia.
15
University of California, Los Angeles, CA, USA.
16
Gustave Roussy Cancer Campus, Villejuif Grand, Paris, France; INSERM U981, Villejuif-Paris-Sud, France.
17
University Hospital Essen, Essen, Germany.
18
H Lee Moffitt Cancer Center, Tampa, FL, USA.
19
Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
20
University of Manchester/The Christie NHS Foundation Trust, Manchester, UK.
PMID:
25638540
DOI:
10.1016/S1470-2045(14)71161-1
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center